Downstream Regulatory Element Antagonist Modulator (DREAM), a target for anti-thrombotic agents.
Downstream Regulatory Element Antagonist Modulator (DREAM), a target for anti-thrombotic agents.
复制标题
DOI：
10.1016/j.phrs.2017.01.002
复制
发表时间：
2017-03
影响因子：
9.3
通讯作者：
Cho J
中科院分区：
文献类型：
--
作者：
Cho J
循环血小板参与许多疾病的形成过程，包括血栓、炎症和癌症。因此，了解疾病条件下介导血小板活化的潜在机制是非常重要的。新出现的证据表明，尽管缺乏细胞核，血小板具有参与有核细胞基因转录的分子。本文将总结下游调控元件拮抗剂调节剂（DREAM），一种转录抑制因子，并重点介绍其在止血和血栓形成中的非转录作用的最新发现。
Circulating platelets participate in the process of numerous diseases including thrombosis, inflammation, and cancer. Thus, it is of great importance to understand the underlying mechanisms mediating platelet activation under disease conditions. Emerging evidence indicates that despite the lack of a nucleus, platelets possess molecules involved in gene transcription occurring in nucleated cells. This review will summarize downstream regulatory element antagonist modulator (DREAM), a transcriptional repressor, and highlight recent findings suggesting its novel non-transcriptional role in hemostasis and thrombosis.